P. Vasey

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

P. Vasey, Stan B. Kaye, Rachel Morrison et al. · PubMed · 1999 · 691 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Andreas du Bois, Michael Quinn, Tate Thigpen et al. · Annals of Oncology · 2005 · 466 citations

Medicine, Gynecology, Oncology +17

Survival and longer-term toxicity results of the SCOTROC study : docetaxel-carboplatin (DC) vs. paclitaxelcarboplatin (PC) in epithelial ovarian cancer (EOC) (abstract)

P. Vasey · Medical Entomology and Zoology · 2002 · 43 citations

Medicine, Oncology, Pharmacology +16

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

Chris Twelves, C. Gardner, A. Flavin et al. · British Journal of Cancer · 1999 · 29 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC)

Charlie Gourley, J F Smyth, Melanie Mackean et al. · Journal of Clinical Oncology · 2006 · 15 citations

Medicine, Oncology, Pharmacology +17